BOSTON SCIENTIFIC CORPORATION Business Acquisition, Pro Forma Net Income (Loss)
BOSTON SCIENTIFIC CORPORATION (BSX) reported Business Acquisition, Pro Forma Net Income (Loss) of $4.58 billion for the 12-month period ending 2019-12-31, per its 10-K filed 2020-02-25.
Discontinued › Expense Statement › Operating Expenses
us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss · last filed 2020-02-25
- BOSTON SCIENTIFIC CORPORATION business acquisition, pro forma net income (loss) for the quarter ending 2019-12-31 was $3.99B, a 1255.78% increase year-over-year.
- BOSTON SCIENTIFIC CORPORATION business acquisition, pro forma net income (loss) for the quarter ending 2019-09-30 was $152.00M, a 54.22% decline year-over-year.
- BOSTON SCIENTIFIC CORPORATION business acquisition, pro forma net income (loss) for the quarter ending 2018-12-31 was $294.00M.
- BOSTON SCIENTIFIC CORPORATION business acquisition, pro forma net income (loss) for the quarter ending 2018-09-30 was $332.00M.
- BOSTON SCIENTIFIC CORPORATION business acquisition, pro forma net income (loss) for fiscal 2019 was $4.58B, a 268.57% increase from fiscal 2018.
- BOSTON SCIENTIFIC CORPORATION business acquisition, pro forma net income (loss) for fiscal 2018 was $1.24B.
| Period end | Business Acquisition, Pro Forma Net Income (Loss) 3 month | Business Acquisition, Pro Forma Net Income (Loss) 6 month | Business Acquisition, Pro Forma Net Income (Loss) 9 month | Business Acquisition, Pro Forma Net Income (Loss) 12 month |
|---|---|---|---|---|
| 2019-12-31 | $3.99B derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $4.14B derived: sum of 2 quarters · filed 2020-02-25 | $4.58B 10-K · filed 2020-02-25 | |
| 2019-09-30 | $152.00M 10-Q · filed 2019-11-05 | $599.00M 10-Q · filed 2019-11-05 | ||
| 2018-12-31 | $294.00M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $626.00M derived: sum of 2 quarters · filed 2020-02-25 | $1.24B 10-K · filed 2020-02-25 | |
| 2018-09-30 | $332.00M 10-Q · filed 2019-11-05 | $950.00M 10-Q · filed 2019-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BECTON DICKINSON & CO (BDX) | United States | $48.834B | 43.79 |
| 3M CO (MMM) | United States | $86.404B | 27.87 |
| DEXCOM INC (DXCM) | United States | $33.004B | 25.42 |
| WEST PHARMACEUTICAL SERVICES INC (WST) | United States | $26.288B | 43.14 |
| STRYKER CORP (SYK) | United States | $103.511B | 32.39 |
| Solventum Corp (SOLV) | United States | $15.085B | 9.16 |
| Penumbra Inc (PEN) | United States | $12.596B | 77.33 |
| BAXTER INTERNATIONAL INC (BAX) | United States | $12.139B | -10.35 |
| GLOBUS MEDICAL INC (GMED) | United States | $9.977B | 20.03 |
| INSULET CORP (PODD) | United States | $9.420B | 28.12 |